![Tasuku Kitada](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Dr. Tasuku Kitada is a President, Director & Head-R&D at Strand Therapeutics, Inc. He is on the Board of Directors at Strand Therapeutics, Inc. Dr. Kitada was previously employed as a Senior Analyst by Candriam Belgium SA.
Tasuku Kitada active positions
| Companies | Position | Start |
|---|---|---|
Strand Therapeutics, Inc.
 Strand Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company with a pipeline of mRNA therapeutics for cancers and autoimmune diseases | Founder | 01/01/2017 |
Former positions of Tasuku Kitada
| Companies | Position | End |
|---|---|---|
Candriam Belgium SA
 Candriam Belgium SA Investment ManagersFinance Candriam Belgium is a long-term, multi-specialist global investment manager that aims to deliver superior investment returns, solutions and service to their clients. They strive to achieve this through a combination of expertise in several key areas, such as fixed income, equities, alternatives, and multi-asset strategies, while embedding ESG considerations into their investment process. The firm's investment philosophy is built on a disciplined process that combines fundamental analysis, ESG analysis and quantitative tools as appropriate. | Analyst-Equity | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
4
1st degree connections
2
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Candriam Belgium SA
Candriam Belgium SA Investment ManagersFinance Candriam Belgium is a long-term, multi-specialist global investment manager that aims to deliver superior investment returns, solutions and service to their clients. They strive to achieve this through a combination of expertise in several key areas, such as fixed income, equities, alternatives, and multi-asset strategies, while embedding ESG considerations into their investment process. The firm's investment philosophy is built on a disciplined process that combines fundamental analysis, ESG analysis and quantitative tools as appropriate. | Finance |
Strand Therapeutics, Inc.
Strand Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company with a pipeline of mRNA therapeutics for cancers and autoimmune diseases | Health Technology |
- Stock Market
- Insiders
- Tasuku Kitada
